Status:
UNKNOWN
Effects of Fasting Strategies on Postoperative Recovery and Long-term Prognosis in Patients With Colorectal Cancer
Lead Sponsor:
Fudan University
Collaborating Sponsors:
Shanghai Cancer Hospital, China
Huashan Hospital
Conditions:
Fasting
Immune Suppression
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
In 2018, colorectal cancer is the third most common malignant tumor in terms of morbidity and second mortality in the world. Surgical resection is still the main treatment for colorectal cancer.With t...
Detailed Description
As early as a century ago, Investigators proved that diet restriction can prevent the occurrence of transplanted tumors in mice. Following this milestone, many animal studies (from mice to primates) h...
Eligibility Criteria
Inclusion
- Age 20 \~ 70 years old
- With BMI 20.5-25.0 kg/m2
- Without any Endocrine and metabolic diseases
- A stable body weight (±3 kg) for at least 6 months
- Those diagnosed with colorectal cancer by preoperative pathology or enteroscopy
- Patients undergoing laparoscopic radical colorectal cancer resection
- ASA grade I-III grade
- Initial patients have not received any treatment for bowel cancer except neoadjuvant chemotherapy
- Patients with confirmed and feasible radical resection of colorectal cancer
- No evidence of distant metastasis before surgery
- Willing to participate in the research of the subject and agree to follow up regularly
Exclusion
- Patients with relapsed colorectal cancer who are going to undergo surgery and re-excision
- accompanied by other malignant tumors
- Severe malnourished patients
- History of systemic metabolism such as diabetes
- Before surgery, have received other treatments for colorectal cancer (such as local excision, etc.) in addition to neoadjuvant chemotherapy
- Have a history of immunotherapy before surgery
- Combined with basic diseases of serious heart, lung, brain, kidney and other important organs
- Combined with severe primary diseases such as severe immune system or hematopoietic system
- The tumor burden cannot be cured, and there is distant metastasis. Those who intend to undergo palliative surgery
- People with gastroesophageal reflux disease, difficulty swallowing, intestinal obstruction, or difficulty in airway management
- People who refuse to participate in the study or cannot receive long-term follow-up
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
2400 Patients enrolled
Trial Details
Trial ID
NCT04345978
Start Date
January 1 2020
End Date
September 30 2023
Last Update
August 11 2020
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Biostatistics, School of Public Health, Fudan University,
Shanghai, Shanghai Municipality, China, 200032
2
Fudan University Huashan Hospital
Shanghai, Shanghai Municipality, China, 200032
3
Fudan University Shanghai Cancer center
Shanghai, Shanghai Municipality, China, 200032
4
Fudan University,ZhongShan Hospital
Shanghai, Shanghai Municipality, China, 200032